Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor

May 2004 in “ The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism ”

Richard V. Clark, David Hermann, Glenn R. Cunningham, Timothy H. Wilson, Betsy Morrill, S. F. Hobbs

dutasteride 5α-reductase inhibitor dihydrotestosterone DHT benign prostatic hyperplasia BPH finasteride Avodart Propecia

TLDR Dutasteride more effectively lowers DHT levels in men with enlarged prostates than finasteride.

The study demonstrated that dutasteride, a dual 5α-reductase inhibitor, significantly suppressed dihydrotestosterone (DHT) levels in men with benign prostatic hyperplasia (BPH) over 24 weeks. Higher doses of dutasteride (2.5 mg and 5.0 mg) resulted in greater DHT suppression (97.7% and 98.4%, respectively) compared to finasteride (70.8%). The study included 399 participants and concluded that dutasteride was more effective in lowering DHT levels and managing BPH symptoms, with a safety profile similar to placebo.

View this study on academic.oup.com →

Discuss this study in the Community →

Cited in this study

7 / 7 results

research The Long-Term Effect of Specific Type II 5alpha-Reductase Inhibition with Finasteride on Bone Mineral Density in Men: Results of a 4-Year Placebo Controlled Trial

37 citations , May 2002 in “PubMed”

research Finasteride in the treatment of men with androgenetic alopecia

581 citations , October 1998 in “Journal of The American Academy of Dermatology”

Finasteride safely and effectively treats male pattern hair loss, but may cause reversible sexual issues and harm male fetuses.

research The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic Hyperplasia

1054 citations , February 1998 in “The New England Journal of Medicine”

Finasteride reduces urinary issues and surgery need in men with enlarged prostates by over 50%.

research Different Levels of 5α-Reductase Type I and II, Aromatase, and Androgen Receptor in Hair Follicles of Women and Men with Androgenetic Alopecia

416 citations , September 1997 in “Journal of Investigative Dermatology”

People with hair loss have more androgen receptors and enzymes in certain follicles, with men and women showing different patterns.

research Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men.

6 citations , August 1996 in “The Journal of Clinical Endocrinology and Metabolism”

MK-386 and finasteride together effectively reduce DHT levels, potentially treating acne and male pattern baldness.

research Effect of finasteride, a 5 alpha-reductase inhibitor, on serum gonadotropins in normal men.

30 citations , August 1992 in “The Journal of Clinical Endocrinology and Metabolism”

Finasteride doesn't affect hormone levels in normal men.

research Effects of Finasteride (MK-906), a 5α-Reductase Inhibitor, on Circulating Androgens in Male Volunteers*

147 citations , April 1990 in “The Journal of Clinical Endocrinology and Metabolism”

Finasteride safely lowers DHT levels without affecting testosterone.

6 / 6 results

research 5-Alpha Reductase Inhibitors in Androgenetic Alopecia: Shifting Paradigms, Current Concepts, Comparative Efficacy, and Safety

19 citations , May 2020 in “Dermatologic Therapy”

Dutasteride works better than finasteride for hair loss, with both being safe to use.

research 5 Alpha-Reductase Inhibitors: What's New?

47 citations , January 2003 in “Current opinion in urology”

A new drug, dutasteride, is at least as effective as the older drug, finasteride, for treating enlarged prostate and may have additional uses.

Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor

Cited in this study

research The Long-Term Effect of Specific Type II 5alpha-Reductase Inhibition with Finasteride on Bone Mineral Density in Men: Results of a 4-Year Placebo Controlled Trial

research Finasteride in the treatment of men with androgenetic alopecia

research The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic Hyperplasia

research Different Levels of 5α-Reductase Type I and II, Aromatase, and Androgen Receptor in Hair Follicles of Women and Men with Androgenetic Alopecia

research Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men.

research Effect of finasteride, a 5 alpha-reductase inhibitor, on serum gonadotropins in normal men.

research Effects of Finasteride (MK-906), a 5α-Reductase Inhibitor, on Circulating Androgens in Male Volunteers*

Related

research 5-Alpha Reductase Inhibitors in Androgenetic Alopecia: Shifting Paradigms, Current Concepts, Comparative Efficacy, and Safety

research What Do We Know About 5-Alpha Reductase Inhibitors?

research Comparison of Clinical Efficacy of Finasteride and Dutasteride as 5-Alpha Reductase Inhibitors

research Comparative Effect of Finasteride and Dutasteride on Chromogranin A Levels

research Comparison of Clinical Trials with Finasteride and Dutasteride

research 5 Alpha-Reductase Inhibitors: What's New?